2215-78-3

Usage

Uses

Used in Organic Synthesis:
(4-Phenoxyphenyl)methanol is used as a reactant and reagent in various organic reactions and synthesis processes. Its unique chemical structure allows it to participate in a wide range of reactions, making it a versatile building block for the synthesis of more complex organic molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, (4-phenoxyphenyl)methanol is used as an intermediate in the synthesis of various drugs and drug candidates. Its ability to participate in a variety of organic reactions makes it a valuable component in the development of new medications with potential therapeutic benefits.
Used in Chemical Research:
(4-Phenoxyphenyl)methanol is also used in chemical research as a model compound to study various organic reactions and mechanisms. Its unique structure and reactivity provide valuable insights into the behavior of similar compounds and contribute to the advancement of organic chemistry.

InChI:InChI=1/C13H12O2/c14-10-11-6-8-13(9-7-11)15-12-4-2-1-3-5-12/h1-9,14H,10H2

Upstream product

• 21218-94-0 methyl 4-phenoxybenzoate 
• 67-36-7 4-phenoxy benzaldehyde 
• 5031-78-7 4-phenoxyacetophenone 
• 1706-12-3 4-phenoxytoluene 
• 1623-95-6 4-phenoxybenzoyl chloride 
• 591-50-4 iodobenzene 
• 623-05-2 (4-hydroxyphenyl)methanol 
• 873-75-6 4-bromobenzenemethanol 
• 108-95-2 phenol 
• 873-76-7 para-Chlorobenzyl alcohol 
• 18282-51-4 4-iodo-benzyl alcohol 
• 108-86-1 bromobenzene 
• 88284-48-4 2-(trimethylsilyl)phenyl trifluoromethanesulfonate 
• 7732-18-5 water 

Downstream Products

• 36881-42-2 1-(bromomethyl)-4-phenoxybenzene 
• 4039-92-3 4-phenoxybenzyl chloride 
• 90296-16-5 (4-Phenoxy-benzyloxy)-acetic acid 
• 93512-64-2 3,3,3-Trifluoro-2-methyl-2-(4-phenoxy-benzyloxy)-propionic acid 
• 93496-93-6 3,3,3-Trifluoro-2-methyl-2-(4-phenoxy-benzyloxy)-propionic acid methyl ester 
• 139259-73-7 p-phenoxybenzyl benzohydroxamate 
• 139259-88-4 p-phenoxybenzyl N-chlorobenzohydroxamate 
• 139259-92-0 N-(acetyloxy)-N-(((4-(phenyloxy)phenyl)methyl)oxy)benzamide 
• 191284-55-6 (1α,2β,3β,4α)-1,3-Di[4-phenoxybenzyloxycarbonyl]cyclobutane-2,4-dicarboxylic acid 
• 2509-23-1 4-Acetoxymethyl-diphenylether 
• 1316649-76-9 C₁₆H₁₄N₄O₃ 
• 1316650-52-8 C₂₀H₁₆N₄O₃S 
• 1316650-82-4 C₂₂H₁₉N₅O₂ 
• 1316651-71-4 C₂₆H₂₁N₅O₂S 

Relevant academic research and scientific papers

Ligand compound for copper catalyzed aryl halide coupling reaction, catalytic system and coupling reaction

The invention provides a ligand compound capable of being used for copper catalyzed aryl halide coupling reaction, the ligand compound is a three-class compound containing a 2-(substituted or non-substituted) aminopyridine nitrogen-oxygen group, and the invention also provides a catalytic system for the aryl halide coupling reaction. Thecatalytic system comprises a copper catalyst, a compound containing a 2-(substituted or non-substituted) aminopyridine nitrogen-oxygen group adopted as a ligand, alkali and a solvent, and meanwhile, the invention also provides a system for the aryl halide coupling reaction adopting the catalyst system. The compound containing the 2-(substituted or non-substituted) aminopyridine nitrogen oxygen group can be used as the ligand for the copper catalyzed aryl chloride coupling reaction, and the ligand is stable under a strong alkaline condition and can well maintain catalytic activity when being used for the copper-catalyzed aryl chloride coupling reaction. In addition, the copper catalyst adopting the compound as the ligand can particularly effectively promote coupling of copper catalyzed aryl chloride and various nucleophilic reagents which are difficult to generate under conventional conditions, C-N, C-O and C-S bonds are generated, and numerous useful small molecule compounds are synthesized. Therefore, the aryl halide coupling reaction has a very good large-scale application prospect by adopting the copper catalysis system of the ligand.

PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS

This disclosure provides pharmaceutical compounds to treat medical disorders, such as complement-mediated disorders, including complement Cl -mediated disorders.

Preparation method of 4-phenoxybenzylalcohol

The invention relates to a preparation method of 4-phenoxybenzylalcohol. The preparation method comprises the specific steps: A, adding a proper amount of dimethyl sulfate, p-fluorobenzaldehyde, phenol, inorganic alkali and cuprous salt into a reaction kettle; stirring and raising the temperature; controlling the temperature to 100 DEG C to 150 DEG C and reacting; after reacting completely, cooling to room temperature; filtering to remove the inorganic salt; then recycling the dimethyl sulfate to obtain 4-phenoxybenzaldehyde and adding the 4-phenoxybenzaldehyde into methanol and dissolving; B,adding a methanol solution containing the 4-phenoxybenzaldehyde and a catalyst into a pressure kettle and controlling the temperature to 50 DEG C to 70 DEG C; introducing hydrogen gas and reacting; keeping the pressure of the hydrogen gas to be 5kg/cm or more; after reacting completely, cooling to the room temperature; filtering under an oxygen-free condition to remove the catalyst; then recycling the methanol; cooling and crystallizing a residual product to obtain the 4-phenoxybenzylalcohol. The preparation method of the 4-phenoxybenzylalcohol, provided by the invention, has a simple route and a high yield.

Preparation method of 4-benzyloxybenzyl alcohol

The invention relates to a preparation method of 4-benzyloxybenzyl alcohol. The preparation method comprises the specific steps: A, adding a proper amount of dimethylformamide, p-fluorobenzaldehyde, phenol, inorganic alkali and cuprous salt in a reaction kettle, stirring to rise the temperature, controlling the temperature at 100 DEG C to 150 DEG C and carrying out a reaction, after completion ofthe reaction, cooling to room temperature, filtering to remove inorganic salt, then recycling dimethylformamide, adding the obtained 4-benzyloxybenzaldehyde in methanol and dissolving; and B, adding the methanol solution of 4-benzyloxybenzaldehyde and a catalyst into a pressure kettle, controlling the temperature at 50 DEG C to 70 DEG C, introducing hydrogen and carrying out a reaction, keeping the hydrogen pressure at 5 kg/cm or more, after completion of the reaction, cooling to room temperature, filtering to remove the catalyst under anaerobic conditions, then recycling methanol, carryingout cooling crystallization of the remaining product, and thus obtaining 4-benzyloxybenzyl alcohol. The preparation method of 4-benzyloxybenzyl alcohol is simple in route and high in yield.

Copper-Catalyzed Diaryl Ether Formation from (Hetero)aryl Halides at Low Catalytic Loadings

Diaryl formation is achieved by coupling phenols and (hetero)aryl halides under the catalysis of CuI/N,N′-bis(2-phenylphenyl) oxalamide (BPPO) or CuI/N-(2-phenylphenyl)-N′-benzyl oxalamide (PPBO) at 90 °C using DMF or MeCN as the solvent. Only 0.2-2 mol % CuI and ligand are required for complete conversion, which represents the lowest catalytic loadings for a general Cu/ligand-catalyzed diaryl ether formation.

COMPOSITIONS AND METHODS FOR REDUCTION OF KETONES, ALDEHYDES AND IMINIUMS, AND PRODUCTS PRODUCED THEREBY

A method of producing an alcohol, comprises reducing an aldehyde or a ketone with a hydridosilatrane. The reducing is carried out with an activator.

HISTONE DEMETHYLASE INHIBITORS

This disclosure relates to compounds that inhibit histone demethylase activity. In particular, the disclosure relates to compounds that inhibit histone lysine demethylase KDM5B, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions disclosed herein.

Silatrane as a Practical and Selective Reagent for the Reduction of Aryl Aldehydes to Benzylic Alcohols

Hydrosilanes are cheap, readily available substrates, yet they do not see as extensive use for simple carbonyl reductions as borohydrides. Hydrosilane reducing agents broadly fall into one of two general categories: either a) they are easy to handle and require expensive and/or hazardous additives, or b) they are difficult and/or dangerous to handle. This work details the discovery of mild and functional group compatible conditions utilizing hydrosilatrane for the selective reduction of aryl aldehydes to benzylic alcohols without unwanted formation of ethers or deoxygenated products. This method offers significant advances in silane reductions as silatrane is an air- and moisture-stable yet relatively reactive reducing agent that can be used in benchtop open air reactions.

CuI/oxalamide catalyzed couplings of (hetero)aryl chlorides and phenols for diaryl ether formation

Couplings between (hetero)aryl chlorides and phenols can be effectively promoted by CuI in combination with an N-aryl-N′-alkyl-substituted oxalamide ligand to proceed smoothly at 120 °C. For this process, N-aryl-N′-alkyl-substituted oxalamides are more effective ligands than bis(N-aryl)-substituted oxalamides. A wide range of electron-rich and electron-poor aryl and heteroaryl chlorides gave the corresponding coupling products in good yields. Satisfactory conversions were achieved with electron-rich phenols as well as a limited range of electron-poor phenols. Catalyst and ligand loadings as low as 1.5 mol % are sufficient for the scaled-up variants of some of these reactions. Aryl and alkyl: N-Aryl-N′-alkyl-substituted oxalamide ligands promote the CuI catalyzed coupling of (hetero)aryl chlorides and phenols at 120 °C more effectively than bis(N-aryl)-substituted oxalamides. A wide range of electron-rich and electron-poor aryl and heteroaryl chlorides were converted into the corresponding coupling products in good yields.

Using the same hydroxamic acid derivative and HDAC8 inhibitor (by machine translation)

Disclosed are: a compound which is capable of inhibiting the function of HDAC8; and an HDAC8 inhibitor. Specifically disclosed is a hydroxamic acid derivative which is characterized by being composed of a compound represented by general formula (1) (wherein X represents an aromatic substituent or an optionally substituted 3-8 membered ring, and n represents an integer of 0-20), or a pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof.